Navigation Links
InVitria Sponsors ESACT 2009 in Dublin, Ireland
Date:6/5/2009

InVitria, a leading supplier of performance enhancing cell culture media supplements, to sponsor the 21st Meeting of the European Society for Animal Cell Technology (ESACT) in Dublin, Ireland from June 7-10, 2009.

Fort Collins, CO June 5, 2009 / b3c newswire / – The world-renowned ESACT ‘09 gathering will serve as host to scientific experts from academia and industry brought together to find “Cellular Solutions for Clinical Challenges.” As one of the sponsors, InVitria will be sharing with attendees the powerful effects of its portfolio of cell culture media supplements developed to solve the regulatory and performance challenges facing the life science industry.

InVitria recently introduced a new product called ZAP-CHO, a performance enhancing cell culture media supplement designed to improve cell growth and antibody production in mammalian cell culture.

“ZAP-CHO improves CHO product development in chemically defined media that are completely free of animal components,” said Steve Pettit, Ph.D., Director of Cell Culture Development with InVitria.  “Previously, the performance enhancements gained with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum or fetal calf serum) in cell culture media,” said Dr. Pettit.

Additionally, ZAP-CHO speeds-up cell line development and seed train expansion and also offers cost saving benefits by reducing operating costs as well as capital investment.
 
Recent publications, along with customer results has validated that another of InVitria’s leading cell culture supplements, Cellastim, a recombinant human serum albumin, outperforms other forms of albumin for growth and productivity. Cellastim is a key component in stem cell media and is used to safely optimize performance in CHO and hybridoma cell lines.

“ESACT is a tremendous venue to build awareness of InVitria’s product portfolio and collaborate with leaders in cellular biology,” said Scott Deeter, InVitria President and CEO. “InVitria’s products provide a unique opportunity for the cellular products industry to advance to a higher level of safety and productivity.”


About InVitria - www.InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.


Contact
Erik H. Vogel
InVitria
Marketing Manager
Phone: 1-800-916-8311
info@InVitria.com
www.InVitria.com


'/>"/>
b3c newswire

Related biology news :

1. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
4. WPI professor receives Fulbright Scholarship to work on tissue engineering in Ireland
5. Darwin anniversary heralds new conservation research era for Northern Ireland
6. Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
7. For good or ill Ireland gains another mammal species
8. Ireland Cancer Center researchers advance stem cell gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... ... development of precision treatments for neurodegenerative diseases, today announced it has issued a ... approach.” This is one of a series of commentaries from ProMIS’s scientific team ...
(Date:2/22/2017)... , Feb 22, 2017 Dublin ... the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, ... report to their offering. ... Global Biological Crop Protection Market is forecasted to ... The strong growth in biopesticide or biological crop protection market is ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA Partners ... MD former Acting Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, ... joined the company as an Expert Consultant. , In Dr. Spyker’s accomplished career, ...
(Date:2/22/2017)... N.C., Feb. 22, 2017  United Therapeutics Corporation (NASDAQ: ... results for the fourth quarter and year ended ... results reflect continued growth as net revenues reached ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and Chief ... to develop and advance our growing product pipeline, ...
Breaking Biology Technology: